Cormorant Asset Management, LP Solid Biosciences Inc. Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$4.6 - $10.13 $1.15 Million - $2.53 Million	-250,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$7.19 - $32.37 $2.9 Million - $13 Million	-402,987 Reduced 61.71%	250,000 $2.3 Million
Q4 2018 Feb 14, 2019	SELL	$21.32 - $46.34 $373,654 - $812,154	-17,526 Reduced 2.61%	652,987 $17.5 Million
Q3 2018 Nov 14, 2018	SELL	$36.35 - $51.7 $561,353 - $798,403	-15,443 Reduced 2.25%	670,513 $31.6 Million
Q2 2018 Aug 14, 2018	SELL	$7.33 - $43.15 $14 - $86	-2 Reduced -0.0%	685,956 $24.4 Million
Q1 2018 May 15, 2018	BUY	$7.19 - $33.17 $4.93 Million - $22.8 Million	685,958 New	685,958 $5.14 Million

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $24.9M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.